You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)在美國肝病研究學會年會口頭報吿IAP拮抗劑APG-1387臨牀進展,呈現功能性治癒慢性乙肝潛力
格隆匯 11-07 07:00

格隆匯11月7日丨亞盛醫藥-B(06855.HK)發佈公吿,公司在第73屆美國肝病研究學會年會(AASLD 2022)上以口頭報吿形式公佈了其在研凋亡蛋白抑制因子(IAP)拮抗劑APG-1387針對中國慢性乙型肝炎(CHB)患者的I期臨牀試驗的研究結果。這是全球層面首次公佈的IAP靶點拮抗劑在CHB領域的臨牀探索結果,並呈現初步的有效性和安全性。

這項臨牀數據顯示,APG-1387在12 mg和30 mg劑量下呈現明顯的抗乙型肝炎病毒(HBV)活性,且與核苷(酸)類似物(NA)序貫治療具有積極的協同作用。這將支持亞盛醫藥進一步推進APG-1387與其他藥物聯合治療實現功能性治癒CHB的臨牀開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account